ArticleEntropy (Basel, Switzerland)2026
Signalling Entropy Across Measurement Scales: A Compositional Dilution Lemma and Cross-Modality Invariance for Information-Theoretic Analysis of Cancer Transcriptomes.
Article in Entropy (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We develop a unified information-theoretic framework for the analysis of cancer transcriptomic dysregulation across measurement modalities. Three functionals capture distributional, network-aware, and joint-dependence aspects of expression: the Shannon entropy with a Miller-Madow correction, the signalling entropy rate over the protein interaction graph, and the Gaussian total correlation on a principal-component projection. A closed-form algebraic expression yields a linear-time algorithm for the signalling entropy rate. A Compositional Dilution Lemma decomposes bulk entropy into intrinsic and compositional contributions, and a Cross-Modality Invariance Proposition provides an empirically falsifiable null hypothesis. Validation uses 700,202 single cells and 3942 bulk samples across five cancer types. Pan-cancer tumour elevation is significant at p<10-7, and cross-modality testing on 4230 observations does not reject the interaction null at p>0.5. The invariance conclusion is corroborated by cancer-level paired sign-flip permutation, cancer-block bootstrap, and empirical distribution function tests, and the prognostic Cox regressions satisfy proportional-hazards diagnostics with cross-validation concordance of 0.696±0.018. Immune deconvolution against the LM22 signature validates cell-type-specific predictions, partitioning cancers into myeloid-driven and lymphoid-driven classes. Breast cancer Cox regressions instantiate the predicted orthogonality of distributional and network-aware functionals after immune adjustment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.